Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01019343 · ClinicalTrials.gov registry record · NA
Physiological Investigations of Movement Disorders
A NA study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- NA
- Development phase
- 1,273
- Enrollment target
NCT01019343: Completed NA study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT01019343 is a NA study that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 1,273 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01019343, a NA study, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- NA
- Development phase
- 1,273 participants
- Enrollment target
Study Summary
Background: * Previous studies have given researchers information on how the brain controls movement, how people learn to make fine, skilled movements, and why some people have movement disorders. However, further research is needed to learn more about the causes of most movement disorders, such as Parkinson's disease. * By using small, specialized studies to evaluate people with movement disorders and compare them with healthy volunteers, researchers hope to learn more about the changes in the brain and possible causes of movement disorders. Objectives: * To better understand how the brain controls movement. * To learn more about movement disorders. * To train movement disorder specialists. Eligibility: * Individuals 18 years of age or older who have had a movement disorder diagnosed by a neurologist and are able to participate based on the specific requirements of the small study. * Healthy volunteers 18 years of age or older. Design: * Participants will have a screening visit with medical history, physical examination, and questionnaire to determine eligibility. Eligible participants will give consent to participate in up to seven additional outpatient visits for study procedures. The number of sessions and the procedures needed for participation depend on specific symptoms. * Participants must avoid drinking alcohol or caffeinated drinks (sodas, coffee, and tea) for at least 2 days (48 hours) before each session. * Potential studies may include magnetic resonance imaging (MRI) scans, functional MRI scans, electroencephalography, magnetoencephalography, transcranial magnetic stimulation, nerve and sensory stimulation, or movement and mental tasks during any of the above procedures. * This study does not provide treatment for movement disorders. Participants will not have to stop any treatment in order to participate.
Primary Outcome
analyze measures such as the amplitude of the BOLD signal (fMRI); tractography between seed and target regions of interest (using DTI); morphometry of brain regions (using VBM); and different neurotransmitter levels in brain regions of interest (using MRS).
Interventions
- PROCEDURE Transcranial Direct Current Stimulation (tDCS)
- DEVICE Eye-tracking Device
- DEVICE Pulsed vibrator
- OTHER Gait Trainer Treadmill (GTT)
- OTHER Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,273 participants |
| Start Date | 2009-12-08 |
| Est. Completion | 2020-10-09 |
| Phase | NA |
What the finished NCT01019343 record still lists
NCT01019343 is an interventional study that assigns participants to a tested intervention. Its 1,273 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Transcranial Direct Current Stimulation (tDCS) is the first listed.
NCT01019343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01019343 about?
NCT01019343 is a clinical study titled "Physiological Investigations of Movement Disorders". Background: * Previous studies have given researchers information on how the brain controls movement, how people learn to make fine, skilled movements, and why some people have movement disorders. However, further research is needed to learn more about the causes of most movement disorders, such as...
What is the current status of trial NCT01019343?
This trial is currently completed. It is a NA study. The enrollment target is 1,273 participants. The study started on 2009-12-08. Estimated completion is 2020-10-09.
What interventions are being tested in trial NCT01019343?
The interventions under investigation include: Transcranial Direct Current Stimulation (tDCS) (PROCEDURE), Eye-tracking Device (DEVICE), Pulsed vibrator (DEVICE), Gait Trainer Treadmill (GTT) (OTHER), Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scales MMSE and MOCA (OTHER).
Who is sponsoring clinical trial NCT01019343?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01019343's enrollment target sits among peer trials
1,273 78th of 2000 higher than 1,923 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- NCT07225504 · 1,275 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- NCT07001800 · 1,276 participants · Phase 2
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
- NCT06790641 · 1,270 participants · NA
Pathways to Perinatal Mental Health Equity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI